Patient Case and Question
|
|
- Janel Hawkins
- 6 years ago
- Views:
Transcription
1 Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida College of Medicine Tampa, Florida Patient Case and Question A 65-year-old violinist is diagnosed with myeloma and receives Revlimid, Velcade, and dexamethasone (RVD) followed by high-dose melphalan and stem cell transplantation and Revlimid maintenance. 2½ years later, her myeloma markers are increased and, in light of persistent left leg pain, a PET-CT is performed and reveals a new lesion there and in a few other areas. Which of the following factors is NOT a consideration for her treatment at this point? A. The amount of neuropathy she has or could develop B. Her travel schedule C. The genetics of her myeloma at the time of her diagnosis D. The presence of bone disease E. None of the above 1
2 What is relapsed/refractory disease? Relapsed: recurrence after a response to therapy Refractory: progression despite ongoing therapy Options for Relapsed/Refractory Disease Continue to Increase When did you relapse from your initial therapy? 6 months >6 months Repeat initial therapy Different therapy Different therapy Stem cell transplant Stem cell transplant Clinical trial 2
3 Factors to Consider in Treatment Selection DISEASE-RELATED Amount of disease CRAB symptoms, rate of progression Duration of response to initial therapy FISH/cytogenetics/genomics profile PRIOR TREATMENT RELATED Prior drug exposure Toxicity of regimen Mode of administration Previous SCT PATIENT-RELATED Pre-existing toxicity Presence of other medical conditions Age/frailty General health Personal lifestyle and preferences FISH, fluorescence in situ hybridization; SCT, stem cell transplant Lonial S. Hematology Am Soc Hematol Educ Program. 2010;303. Available Anti-Myeloma Agents: So Many Choices! Steroids Prednisone Dexamethasone Conventional Chemo Melphalan Cyclophosphamide Doxil IMiDs Thalomid (thalidomide) Revlimid (lenalidomide) Pomalyst (pomalidomide) Proteasome Inhibitors Velcade (bortezomib) Kyprolis (carfilzomib, [low/high dose]) Ninlaro (ixazomib) HDAC inhibitors Farydak (panobinostat) Monoclonal antibodies Darzalex (daratumumab: anti CD38) Empliciti (elotuzumab: anti CS1/SLAMF7) DCEP/D-PACE BCNU Bendamustine Overcome resistance: Keytruda Viracept (nelfinavir) (pembrolizumab) Venclexta (venetoclax) 3
4 Options at First Relapse Proteasome Inhibitor: Kyprolis (carfilzomib) In combination with dex or with Revlimid + dex for the treatment of patients with relapsed or refractory MM who have received one to three lines of therapy As a single agent for the treatment of patients with relapsed or refractory MM who have received one or more lines of therapy 87% overall response rate when combined with Rev/dex 77% overall response rate when combined with dex Overall response rates as monotherapy 50% in patients who had two or more lines of prior therapy 23% in patients with at least two or more lines of prior therapy 50% in patients who were Velcade-naïve and had one to three prior lines of therapy High-risk features (for example, t(4;14) or 17p13 del or elevated β2-microglobulin) History of previous neuropathy Safe for patients with reduced kidney function Standard: Kyprolis used alone or in combination with dex or in combination with Revlimid and dex Under investigation: combinations with Farydak, IMiDs such as Revlimid and Pomalyst, experimental therapies (for example, SAR650984, filanesib) Overall response rate = complete response (CR) + very good partial response (VGPR) + partial response (PR) + minimal response (MR) 4
5 Proteasome Inhibitor: Kyprolis (carfilzomib) How is Kyprolis administered? Intravenous Given on two consecutive days each week for three weeks (that is, days 1, 2, 8, 9, 15, and 16) followed by a 12-day rest period (days 17 28) What are the possible side effects? What are important additional medications to take? Common side effects include: Fatigue Anemia Nausea Low platelet count Shortness of breath Diarrhea Fever Shingles prevention pills Proteasome Inhibitor: Ninlaro (ixazomib) In combination with Revlimid and dex for the treatment of patients with MM who have received at least one prior therapy 78% overall response rate (PR or better) Relapsed or relapsed/refractory following at least one prior therapy Standard: With Revlimid and dex Under investigation: with Treanda or Pomalyst in RR patients or with Revlimid in newly diagnosed patients 5
6 Proteasome Inhibitor: Ninlaro (ixazomib) How is Ninlaro administered? Oral Days 1, 8, and 15 of a 28-day cycle What are the possible side effects? What are important additional medications to take? Common side effects include: Diarrhea Constipation Thrombocytopenia Peripheral neuropathy Nausea Peripheral edema Vomiting Back pain Shingles prevention pills Monoclonal Antibody: Empliciti (elotuzumab) In combination with Revlimid and dex for the treatment of patients with MM who have received one to three prior therapies 78.5% overall response rate (PR or better) Relapsed or relapsed/refractory following at least one to three prior therapies Standard: with Revlimid and dex Under investigation: with Revlimid and Velcade in newly diagnosed patients; with Pomalyst and nivolumab or Pomalyst and Velcade in RR patients 6
7 Monoclonal Antibody: Empliciti (elotuzumab) How is Empliciti administered? IV Every week for the first two cycles and every 2 weeks thereafter What are the possible side effects? Common side effects include: Fatigue Diarrhea Pyrexia Constipation Cough Peripheral neuropathy Nasopharyngitis Upper respiratory tract infection Decreased appetite Pneumonia Monoclonal Antibody: Daratumumab Combinations Treatment of patients with MM who have received at least one prior therapy in combination with bortezomib and dex (DVd) or in combination with lenalidomide and dex (DRd) 83% overall response rate in combination with bortezomib and dex 93% overall response rate in combination with lenalidomide and dex Relapsed or relapsed/refractory following at least prior line of therapy Standard: with Velcade and dex or with Revlimid and dex Under investigation: with Kyprolis 7
8 Monoclonal Antibody: Darzalex (daratumumab) How is Darzalex administered? IV Weekly for weeks 1 to 8 then every 2 weeks for weeks 9 to 24 and then every 4 weeks for weeks 25 onwards What are the possible side effects? Common side effects include: Infusion reactions Fatigue Nausea Back pain Pyrexia Cough Upper respiratory tract infection Special consideration What are important additional medications to take? Can affect blood typing; carry a card that lists your blood type and indicates that you are on dara Shingles prevention Options at Second Relapse and Beyond 8
9 IMiD: Pomalyst (pomalidomide) For MM patients who have received at least two prior therapies including Revlimid and Velcade and have demonstrated disease progression on or within 60 days of completion of the last therapy 23.5% overall response rate in patients who received two or more prior therapies, including Velcade and Revlimid Received two or more prior therapies, including Velcade and Revlimid High-risk myeloma with DNA alterations, including t(4;14); preliminary data indicates effectiveness in 17p13del Safe for patients with reduced kidney function Patients of all ages Standard: Pomalyst + dex Under investigation: combinations with Vel-dex, Kyprolis-dex; experimental drugs (for example, SAR650984, Filanesib, Ixazomib) IMiD: Pomalyst (pomalidomide) How is Pomalyst administered? What are the possible side effects? What are important additional medications to take? Capsule taken once daily for 21 days out of a 28-day cycle (3 weeks on, 1 week off) Blood thinners (for example, aspirin or low-molecule-weight heparin) are given along with Pomalyst to reduce the risk of blood clots Common side effects include: Fatigue and weakness Low white blood cell counts Anemia Gastrointestinal effects (constipation, nausea, or diarrhea) Shortness of breath Upper respiratory infection Back pain Fever Blood clots* Blood thinners *Reduced risk when taken with blood thinners 9
10 Histone Deacetylase Inhibitor: Farydak (panobinostat) In combination with Velcade and dex, treatment of MM patients who have received at least two prior regimens including Velcade and an IMiD (for example, Thalomid, Revlimid) 58.5% overall response rate (PR or better) Relapsed or relapsed/refractory following at least two prior regimens including Velcade and an IMiD Standard: with Velcade and dex Under investigation: with Kyprolis and experimental drugs (for example, Ninlaro) Histone Deacetylase Inhibitor: Farydak (panobinostat) How is Farydak administered? Oral Taken once every other day for three doses per week of weeks 1 and 2 of a 4-week cycle (that is, on days 1, 3, 5, 8, and 12) What are the possible side effects? What are important additional medications to take? Common side effects include: Diarrhea Peripheral neuropathy Asthenia/fatigue Nausea Peripheral edema Decreased appetite Vomiting Anti-diarrheal medication 10
11 Monoclonal Antibody: Darzalex (daratumumab) Treatment of patients with MM who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory (IMiD) agent 29% overall response rate in patients who had at least three prior lines of therapy including PI and IMiD or were double-refractory to a PI and IMiD 36% overall response rate in patients with at least two different cytoreductive therapies Relapsed or relapsed/refractory following at least three prior lines of therapy including a PI and an immunomodulatory agent or who are doublerefractory to a PI and an immunomodulatory agent Under investigation: with Pomalyst and dex Phase 3 Clinical Studies for Relapsed/Refractory Patients Monoclonal Antibodies Revlimid + dex ± Empliciti Velcade + dex ± Darzalex Revlimid + dex ± Darzalex Pomalyst + dex ± Pembrolizumab* Empliciti + Pomalyst Nivolumab* + dex Currently Available Agents Revlimid* + dex ± Ninlaro* Kyprolis* + dex vs Velcade* + dex Pomalyst* + Velcade* + low-dose dex Kyprolis* (oncevs twice-weekly) + dex Ask your doctor if you are a candidate for clinical trials. Many phase 1 and 2 trials of new drugs and new combinations *Experimental therapy not yet FDA approved 11
12 Special Circumstances High disease burden requiring rapid response: 96-hour continuous IV chemo: V(DCEP) = Velcade + (dex + Cytoxan + etoposide + platinum) VDTPACE = VDCEP + thalidomide + doxorubicin If blood counts low, need a bridge to a clinical trial, and stem cells remaining Consider second (or salvage) autologous stem cell transplant Patient Case, Update A 65-year-old violinist is diagnosed with myeloma and receives Revlimid, Velcade, and dexamethasone (RVD), followed by high-dose melphalan and stem cell transplantation, and Revlimid maintenance. 2½ years later, her myeloma markers are increased and, in light of persistent left leg pain, a PET-CT is performed and reveals a new lesion there and in a few other areas. Because her myeloma had t(4;14) and she had no neuropathy (including when she received Velcade) she and her oncology team decided upon a Velcadebased regimen: Darzalex, Velcade, and dexamethasone. Her pain promptly disappeared and she achieved a very good partial response after four cycles. 12
13 Making Anti-Myeloma Agents Patient Friendly Steroids Prednisone Dexamethasone Oral or IV Conventional Chemo Melphalan Oral or IV In or Outpt SCT Cyclophosphamide Oral or IV Doxil IMiDs Thalomid (thalidomide) Bedtime Revlimid (lenalidomide) Welchol or Prednisone Pomalyst (pomalidomide) 2 or 4 mg Proteasome Inhibitors Velcade (bortezomib) Skin or IV Weekly Kyprolis (carfilzomib, [low/high dose]) Weekly Ninlaro (ixazomib) HDAC Inhibitors Farydak (panobinostat) Every other week Monoclonal Antibodies Darzalex (daratumumab: anti CD38) Skin formulation Empliciti (elotuzumab: anti CS1/SLAMF7) Monthly DCEP/D-PACE In or Outpt BCNU Bendamustine Days 1, 2 or 1, 4 Overcome resistance: Keytruda Viracept (nelfinavir) (pembrolizumab) Venclexta (venetoclax) Ask about co-pay assistance and travel assistance programs! Relapsed/Refractory Myeloma: Choice Is Good! Relapsed/refractory multiple myeloma is treatable Patients typically receive multiple lines of therapy Treatment may sometimes be continued for an extended period Six new drugs (Kyprolis, Pomalyst, Farydak, Darzalex, Empliciti, Ninlaro) introduced in last 4 years With the introduction of each new drug, potential for additional combinations Many promising new drugs/new combinations in clinical development consider a clinical trial 13
Treatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationMultiple Myeloma Update PMMNG 13 Feb Outline. Alfred Garfall MD Edward Stadtmauer MD
Multiple Update PMMNG 13 Feb 2016 Alfred Garfall MD Edward Stadtmauer MD Outline w Updates on existing/approved drugs for multiple myeloma w Updates on new/upcoming drugs and strategies for multiple myeloma
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives Discuss use of standard myeloma therapies when used as therapy
More informationTREATMENT OVERVIEW themmrf.org
MULTIPLE MYELOMA TREATMENT OVERVIEW themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationA Caregiver s Guide to Helping Myeloma Patients. Webinar 1, February 23, 2017 The New Normal for Caregivers of Patients With Multiple Myeloma
A Caregiver s Guide to Helping Myeloma Patients The New Normal for Caregivers of Patients With Multiple Myeloma Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut
More informationMultiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationMultiple. Powerful thinking advances the cure.
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure www.arztol.com Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation
More informationMultiple Myeloma Research Consortium Clinical Trial Pipeline
Multiple Myeloma Research Consortium Clinical Trial Pipeline Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 High-Risk
More informationMore Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D.
More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D. Please remember the opinions expressed on Patient Power are not
More informationJefferies 2017 Healthcare Conference
Jefferies 2017 Healthcare Conference June 9, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The
More informationSafety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed, or Relapsed and Refractory Multiple Myeloma
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed, or Relapsed and Refractory Multiple Myeloma Torben Plesner 1, Hendrik-Tobias Arkenau 2, Henk M Lokhorst 3, Peter Gimsing
More informationThe Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma
Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 1, August 13, 2015 Antibodies: The Body s Foot Soldiers in the Battle Against Disease Speakers Moderator: Joseph Mikhael,
More informationManagement of Multiple Myeloma: The Changing Paradigm. Clinical Trials
Management of Multiple Myeloma: The Changing Paradigm Clinical Trials Goal of Clinical Trials: Making Progress Against Myeloma Increase understanding of the disease Improve the way we use currently available
More informationManaging Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
More informationVELCADE (bortezomib) injection
Multiple Myeloma Cancer of the Bone Marrow Understanding VELCADE (bortezomib) injection u-vel_en_2019_r1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada)
More informationFARYDAK (panobinostat) oral capsule
FARYDAK (panobinostat) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationApplication supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
Media Inquiries: Satu Glawe Phone: +49 172 294 6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationRelapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents
Welcome to Managing Myeloma. My name is Adam Cohen, and I am the Director of Myeloma Immunotherapy and an Assistant Professor in the Hematology/Oncology Division at Abramson Cancer Center of the University
More informationTo learn more about the MMRF, visit or call Accredited by: 2015 Multiple Myeloma Reseach Foundation
ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION Shortly after being diagnosed with multiple myeloma, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF in 1998
More informationDaratumumab (Darzalex )
Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides
More informationHistory of Drug Development in Multiple Myeloma
History of Drug Development in Multiple Myeloma Myeloma Research Roundtable Scottsdale, AZ March 22, 2013 Robert A. Kyle, MD Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1 Disclosures
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Prof Gordon Cook Professor of Haematology and Myeloma Studies University of Leeds & Leeds Cancer Centre #MyelomaInfodays This talk will cover The
More informationCombined Treatments and Clinical Trials for Better Outcomes in Multiple Myeloma
Combined Treatments and Clinical Trials for Better Outcomes in Multiple Myeloma AZMN Patient Conference March 23, 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD,
More informationMultiple Myeloma: Relapsed and Refractory
Multiple Myeloma: Relapsed and Refractory David H. Vesole, MD, PhD, FACP Director, Myeloma Program Professor of Medicine Georgetown University Co-Division Chief, Director of Research Multiple Myeloma Division
More informationMyeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline:
Myeloma XII (ACCoRd) This Infosheet provides information about what the Myeloma XII clinical trial is, why it is taking place and what is involved if patients decide to take part in the trial. This Infosheet
More informationKYPROLIS (carfilzomib) injection
Multiple Myeloma Cancer of the Bone Marrow Understanding KYPROLIS (carfilzomib) injection u-kypro_en_2018_t8 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA
More informationKyprolis. Kyprolis (carfilzomib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.24 Subsection: Antineoplastic Agents Original Policy Date: October 24, 2012 Subject: Kyprolis Page:
More informationTreatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc deliberated upon input from one patient advocacy group and input from registered clinicians regarding the use of daratumumab in patients with multiple myeloma. perc noted that both the patient advocacy
More informationFour Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014
Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,
More informationClinical Advances in Immunotherapy in Myeloma. Webinar 1, June 14, 2017 Monoclonal Antibodies. Speakers
Clinical Advances in Immunotherapy in Myeloma Webinar 1, June 14, 2017 Monoclonal Antibodies Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut Faculty: Tom Martin,
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationFARYDAK (panobinostat) capsules
Multiple Myeloma Cancer of the Bone Marrow Understanding FARYDAK (panobinostat) capsules u-fary_en_2018_c3 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA &
More informationMultiple Myeloma (MM): Diagnosis, Treatment and Side Effects Management. Transcript. Slide Name & Number
Question 1) Multiple myeloma is a disease of: a) Hematopoietic stem cells b) Reticulocytes c) Plasma cells d) Mature lymphocytes 2) What is the acronym for the criteria used to guide therapy initiation
More informationClinical Trials in Multiple Myeloma in Arizona: Past, Present and Future
Clinical Trials in Multiple Myeloma in Arizona: Past, Present and Future AZMN Roundtable March 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Staff
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationJP Morgan Healthcare Conference January 2019
Targeting Disease at the Nuclear Pore JP Morgan Healthcare Conference January 209 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within
More informationClinical Policy: Thalidomide (Thalomid) Reference Number: ERX.SPMN.95
Clinical Policy: (Thalomid) Reference Number: ERX.SPMN.95 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationGSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
More informationTRANSCRIPT Understanding Next in Class Novel Therapies in Multiple Myeloma: New Classes and Targets
Welcome and Introductions [Slide 1] Thank you so much. Hello everyone and thank you so much for joining us. [Slide 2] This is Joan Levy, and I am the Vice President of Research for the Multiple Myeloma
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Hans Lee, MD Assistant Professor Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center No Disclosures
More informationEmerging treatments in Multiple myeloma. Josh Veatch Damian Green
Emerging treatments in Multiple myeloma Josh Veatch Damian Green Emerging treatments in multiple myeloma Introduction Daratumumab Elotuzumab PD 1 inhibitors HDAC inhibitors Other emerging therapies in
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationNINLARO. Understanding. (ixazomib) capsules. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation
Multiple Myeloma Cancer of the Bone Marrow Understanding NINLARO (ixazomib) capsules u-nin_en_2018_f4 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada)
More informationPOMALYST. Understanding. (pomalidomide) capsules. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation
Multiple Myeloma Cancer of the Bone Marrow Understanding POMALYST (pomalidomide) capsules u-pom_en_2018_n7 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA &
More informationThank you, Lizette. I d like to add my welcome to the patients, caregivers and healthcare professionals attending the program today.
WELCOME AND INTRODUCTION Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Larry Anderson for sharing his time and expertise with us
More informationTargeting Disease at the Nuclear Pore. Corporate Presentation March 2019
Targeting Disease at the Nuclear Pore Corporate Presentation March 209 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning
More informationIMMUNOTERAPIA NEL MIELOMA MULTIPLO E NEL LINFOMA DI HODGKIN: Ruolo nel paziente con MM ricaduto
IMMUNOTERAPIA NEL MIELOMA MULTIPLO E NEL LINFOMA DI HODGKIN: Ruolo nel paziente con MM ricaduto Monica Galli UO Ematologia ASST - Ospedale Papa Giovanni XXIII Bergamo Milano, 9 Novembre 2017 MM: New Treatment
More informationMULTIPLE MYELOMA Disease Overview
Speak to a patient support nurse PH: 1.866.603.6628 Email: patientnavigator@themmrf.org MULTIPLE MYELOMA Disease Overview Place stamp here Multiple Myeloma Research Foundation 383 Main Avenue, 5th Floor
More informationMULTIPLE MYELOMA Disease Overview
MULTIPLE MYELOMA Disease Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney,
More informationGenmab Announces U.S. FDA Approval of DARZALEX (daratumumab) for Relapsed Multiple Myeloma and Updates Financial Guidance
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for relapsed or refractory multiple myeloma Financial
More informationMULTIPLE MYELOMA. on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple
MULTIPLE MYELOMA SANDRA E. KURTIN, RN, MS AOCN, ANP-C Our next session is on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma. Pleased to have here with us today, Ms.
More informationLiving With Myeloma Treatment and Side Effects Management
Slide 1: Welcome & Introductions OPERATOR: Hello, everyone, and welcome to Living With Myeloma Treatment and Side Effects Management, a free telephone/web education program. It is my pleasure to introduce
More informationMultiple myeloma Forecast DMKC Published on 07/04/2016
Multiple myeloma Forecast DMKC0157485 Published on 07/04/2016 Datamonitor Healthcare forecasts that the extended indications for these drugs will lead to considerable uptake across the treatment algorithm,
More informationBUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY. Myeloma Canada s experience
BUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY Myeloma Canada s experience WHO WE ARE Myeloma Canada is a registered non-profit organization created by, and for people living with multiple
More informationMyeloma Treatment and Side Effects Management Update
1 Slide 1: Myeloma Treatment and Side Effects Management OPERATOR: Hello, everyone, and welcome to Myeloma Treatment and Side Effects Management Update, a free telephone/web education program. It is my
More informationMyeloma. Anne Grace, myeloma survivor. Support for this publication provided by
Myeloma Anne Grace, myeloma survivor Support for this publication provided by Revised 2017 Publication Update Myeloma The Leukemia & Lymphoma Society wants you to have the most up-to-date information about
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationMember Resources PMMNG Updates/Meetings/Webinars Check our Website and Facebook account often!
PMMNG Website http://philadelphia.myeloma.org/ PMMNG Facebook www.facebook.com/pmmng Member Resources PMMNG Updates/Meetings/Webinars Check our Website and Facebook account often! Publications IMF Multiple
More informationPomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma second line and beyond
NIHR Innovation Observatory Evidence Briefing: September 2017 Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma second line and beyond NIHRIO (HSRIC)
More informationThe Myeloma Guide Information for Patients and Caregivers
The Myeloma Guide Information for Patients and Caregivers Manuel, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The
More informationMultiple myeloma breakthrough 2018
Multiple myeloma breakthrough 2018 Carfilzomib Can Lead to Cardiovascular Toxicity in Multiple Myeloma Patients. Get the latest science news with ScienceDaily's free email newsletters, updated daily and
More informationAndrew Schorr: Dr. Stadtmauer, related to multiple myeloma what is the role of transplant today?
The Ongoing Role of Transplant for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Edward Stadtmauer, M.D. Please remember the opinions expressed on Patient
More informationYgalo - Targeted Alkylator for the Treatment of Myeloma. Pareto Healthcare Conference: September 7 th, 2017
Ygalo - Targeted Alkylator for the Treatment of Myeloma Pareto Healthcare Conference: September 7 th, 2017 Disclaimer IMPORTANT: You must read the following before continuing. The following applies to
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationManaging Your Myeloma
Managing Your Myeloma Managing Your Myeloma Craig Emmitt Cole, MD Assistant Professor of Internal Medicine Multiple Myeloma and Plasma Cell Dyscrasia Program Division of Hematology/Oncology University
More informationDaratumumab for multiple myeloma: A journey from phase 1 towards approval for marketing
Daratumumab for multiple myeloma: A journey from phase 1 towards approval for marketing Torben Plesner, MD University of Southern Denmark & Vejle Hospital Summary Multiple myeloma is a rare hematological
More informationVenetoclax (Venclyxto )
Venetoclax (Venclyxto ) This Horizons Infosheet contains information on venetoclax, a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides information relating to
More informationClinical Trials. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation
Multiple Myeloma Cancer of the Bone Marrow Understanding Clinical Trials u-clintrials_en_2018_l5 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada) 818.487.7455
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Craig Emmitt Cole, MD University of Michigan Comprehensive Cancer Center What are Blood Cancers, What IS Multiple Myeloma?
More informationImmunotherapy in myeloma
Immunotherapy in myeloma Horizons Infosheet Clinical trials and novel drugs This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons
More informationThalidomide Therapy. Understanding. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding Thalidomide Therapy u-thal_en_2017_e1 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada)
More informationThe MMRF CoMMpass Study SM in Context
The MMRF CoMMpass Study SM in Context A Look at the Past, Present, and Future of Multiple Myeloma Research themmrf.org Table of Contents General Overview... 3 Multiple Myeloma Research Foundation: Who
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma December 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Daratumumab (Darzalex) for Multiple Myeloma December 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationHEAD-TO-HEAD PHASE 3 TRIAL OF KYPROLIS (CARFILZOMIB) VERSUS VELCADE (BORTEZOMIB) MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL
ONO PHARMACEUTICAL CO.,LTD. Corporate Communications Mail:public_relations@ono.co.jp March 2, 2015 HEAD-TO-HEAD PHASE 3 TRIAL OF KYPROLIS (CARFILZOMIB) VERSUS VELCADE (BORTEZOMIB) MET PRIMARY ENDPOINT
More informationTRANSCRIPT. Managing Your Myeloma Patient Education Telephone/Web Program WELCOME AND INTRODUCTION. Lizette Figueroa-Rivera, MA
WELCOME AND INTRODUCTION Lizette Figueroa-Rivera, MA Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Craig Cole for sharing his time
More informationPrincess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017
Princess Margaret Cancer Centre Multiple Myeloma Day Introduction Anca Prica MD, MSc, FRCPC May 12, 2017 Who are you? 1) Physician 2) Nurse 3) Pharmacist 4) Trainee 5) Other How many times have you been
More informationRestrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
More informationUnderstanding. (pomalidomide) capsules. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding POMALYST (pomalidomide) capsules u-pom_en_2017_m3 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873)
More informationASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014
ASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014 Robert Orlowski, MD, PhD Director of Myeloma and Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics,
More informationMyeloma 101 Updates and Pain Management Perspectives
Myeloma 101 Updates and Pain Management Perspectives Brian GM Durie, MD Thursday, November 19 th, 2015 Topics for Discussion 1. What to expect from ASH 2015 a preview Research Clinical pearls : New 101
More informationA Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre
A Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre April 2013 Table of Contents 1 Introduction 2 Your Support 3 Thank you 10 The Princess Margaret
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationNovel Targets in Multiple Myeloma
Novel Targets in Multiple Myeloma Ajai Chari, MD Abstract Despite the availability of 5 classes of drugs for the treatment of multiple myeloma (MM), the disease remains incurable in most cases, with patients
More informationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul G. Richardson, M.D., Bart Barlogie, M.D., Ph.D., James Berenson, M.D., Seema Singhal, M.D., Sundar Jagannath, M.D., David Irwin, M.D.,
More informationExpensive Drugs Are Making Us Sick!
Expensive Drugs Are Making Us Sick! Stacy Borans, MD Founder/Chief Medical Officer Advanced Medical Strategies stacy.borans@mdstrat.com Legal Mumbo Jumbo All Slides are protected by AMS Copyright 2016
More informationAffimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
More informationPharmaceutical Approvals Monthly
Pharmaceutical Approvals Monthly January 2011 Volume 16 Number 1 Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials Bolstered by a huge patient database, the Multiple Myeloma Research
More informationImmuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma
Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Stanley R. Frankel, MD, FACP Corporate Vice President, Clinical R & D Head, Immuno-Oncology Celgene Cancer Progress
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationDRUGS LIFESPAN FOR PATIENTS DECADE TRIPLING THE IN THE LAST SURVIVAL IMPROVEMENT
10 40 % 3 IMPROVEMENT DRUGS IN THE LAST DECADE IN 5 YEAR SURVIVAL X TRIPLING THE LIFESPAN FOR PATIENTS 4 Drugs Approved in 2015! FDA APPROVALS IN 2015 Drug FDA Approval Panobinostat (Farydak ) February
More informationAdvances in Multiple Myeloma
Advances in Multiple Myeloma Dates of Certification: August 21, 2015, to August 21, 2016 Medium: Print with online posttest, evaluation, and request for credit Medical Writer Cheryl Zigrand Disclosure:
More informationAMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS (CARFILZOMIB) FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
January 29, 2015 ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp AMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS Amgen (NASDAQ:AMGN) and its subsidiary Onyx
More informationTechnology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta457
Carfilzomib for previously treated multiple myeloma Technology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta457 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationInfopack for relapsed and/or refractory myeloma patients. Infoline:
Infopack for relapsed and/or refractory myeloma patients. 1 1 What is relapsed myeloma? 2 How will I know if I am relapsing? 3 Can the timing of relapse be predicted? 4 Treatment at relapse 5 Refractory
More informationTORONTO & DISTRICT MULTIPLE MYELOMA SUPPORT GROUP NEWSLETTER Website:
TORONTO & DISTRICT MULTIPLE MYELOMA SUPPORT GROUP NEWSLETTER Website: www.myelomatoronto.ca May 2018 Newsletter # 124 In This Issue Next Meeting Details Last Meeting Announcements: Upcoming Guest Speakers
More information